Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria Bioscience (NASDAQ:LEXX) began dosing on June 14, 2026 in Human Pilot Study #7 (GLP-1-H26-7), a 5-week trial of two oral DehydraTECH-semaglutide (DHT-sema) formulations versus Novo Nordisk’s Wegovy tablets.
The three-arm study compares SNAC-inclusive DHT-sema tablets and capsules with Wegovy under fasted conditions, aims to reach steady-state semaglutide levels, evaluates safety, tolerability and pharmacokinetics, tests new tablet properties modeled on Rybelsus/Wegovy, and is fully funded from existing resources.
Lexaria Bioscience (NASDAQ:LEXX) began dosing for Animal Study #1 (GLP-1-A26-1) on June 10, 2026, on schedule. The study tests DehydraTECH-semaglutide and DehydraTECH-CBD GLP-1 compositions in Sprague-Dawley rats across 11 arms, with pharmacokinetics and brain drug levels measured.
Results are expected by early September and the work is fully funded. Lexaria has filed 3 new patent applications related to alternative SNAC-like formulations and received its first Australian patent in Family #21 for hypertension (patent #2023302884, expiring April 25, 2043).
Lexaria Bioscience (NASDAQ:LEXX) reports on accelerating GLP-1 adoption and expanding indications for obesity, diabetes and related diseases. Novo’s oral Wegovy has surpassed three million US prescriptions and gained approvals in the UAE and UK, while Lilly reports strong Phase 3 results for retatrutide and oral GLP-1 Foundayo.
Lexaria is advancing its DehydraTECH oral drug delivery platform, targeting improved GLP-1 absorption and fewer gastrointestinal adverse events. In animal studies, DehydraTECH formulations of semaglutide, tirzepatide and liraglutide reduced GI AEs by 31%–100%. New 2026 animal studies will evaluate retatrutide and amycretin with DehydraTECH.
Lexaria Bioscience (NASDAQ:LEXX) has completed dosing in its 2026 Animal Study #2 (GLP-1-A26-2) examining DehydraTECHTM formulations of next-generation GLP-1 drugs retatrutide and amycretin.
The 18-arm study measures pharmacokinetics and tolerability, compares tablets vs capsules, explores sodium caprate-based delivery, and is self-sponsored using existing corporate resources.
Lexaria Bioscience (NASDAQ:LEXX) will attend the BIO International Convention in San Diego from June 22-25, 2026, as part of its broader business development program.
The company reports record-high collaboration interest in its proprietary DehydraTECH oral drug delivery platform and expects a fully booked meeting schedule.
Lexaria Bioscience (NASDAQ:LEXX) received independent ethics board approval for Human Pilot Study #7 (GLP-1-H26-7) to evaluate two oral DehydraTECH-semaglutide (DHT-sema) formulations against Novo Nordisk's Wegovy tablets.
The five-week, fully funded, parallel-group study will assess safety, tolerability and pharmacokinetics under fasted conditions, including first-time multi-week SNAC-inclusive tablet and capsule DehydraTECH compositions.
Lexaria Bioscience (NASDAQ:LEXX) released the second episode of its investor series on May 7, 2026, featuring CEO Rich Christopher discussing a Material Transfer Agreement extension through year-end 2026 with a global pharmaceutical partner and the company’s 2026 GLP-1 research priorities. The episode outlines plans to generate clinical data this year and continued business development activity tied to DehydraTECH and oral drug delivery programs.
Additional episodes will cover the clinical pipeline, intellectual property, and commercial strategy.
Lexaria (NASDAQ:LEXX) updated progress on Human Pilot Study #7 (GLP-1-H26-7), which will compare two DehydraTECH-semaglutide (DHT-sema) compositions to Wegovy tablets under fasted conditions.
Ethics submissions are filed, tablet manufacturing is complete, third-party QC testing is underway, and Lexaria anticipates Pre-Dosing Tasks done by early June with dosing expected mid‑June; the Study is fully funded.
Lexaria (NASDAQ:LEXX) launched Reformulated: Into the Mainstream, an ongoing investor video series to increase transparency and engagement with shareholders.
The inaugural episode features CEO Rich Christopher discussing the DehydraTECH platform, applicability across GLP-1 therapies, CBD and antivirals, the ~$75 billion GLP-1 market in 2025, completion of five human GLP-1 studies, and outlicensing activity under an active Material Transfer Agreement with a global pharmaceutical company.
Lexaria (NASDAQ:LEXX) announced an extension of its Material Transfer Agreement with a pharmaceutical company through December 31, 2026 to allow review of Lexaria's 2026 GLP-1 R&D results.
The extension keeps the temporary exclusive license active, allows continued collaboration talks, and supports ongoing Human Study #7 and Animal Studies #1 and #2, all funded by existing corporate resources with results expected in Q3–Q4 2026.